title: Successful treatment of low turnover osteoporosis resulting from prolonged reserpine therapy with intermittent calcitonin and phosphate therapy.
abstract: Coherence therapy, popularly known by the acronym ADFR (Activate, Depress, Free, Repeat), was designed to increase bone mass in osteopenic patients. Accordingly, we report a case of a hypogonadal male with histologically proven low bone turnover osteoporosis and a progressive vertebral fracture syndrome, who responded favorably to ADFR treatment with the use of salmon calcitonin and inorganic phosphate. Dramatic increments in bone mass were observed during a 68-month period of therapy. Serial quantitative computerized tomography demonstrated a 146% increase from baseline in bone mineral density for the first 30 months of treatment, and dual energy radiography yielded a 36.5% increase for the subsequent 31-68 months. Furthermore, no episode of fracture occurred since coherence therapy was initiated.
authors.affiliation: Division of Bone and Mineral Diseases, Washington University Medical Center, St. Louis, Missouri.
authors.forename: R C
authors.initials: RC
authors.lastname: Armamento-Villareal
authors.forename: L V
authors.initials: LV
authors.lastname: Avioli
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy*; D010710:Phosphates / Q000627:therapeutic use*; D012110:Reserpine / Q000009:adverse effects*; D013122:Spinal Diseases / Q000139:chemically induced / Q000188:drug therapy
chemical_list: D010710:Phosphates; C028815:salmon calcitonin; D012110:Reserpine; D002116:Calcitonin